pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.jpg 144 Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients IRVINE, Calif., Aug 31, 2010 -- Allergan, Inc. (NYSE:AGN) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN(R) (bimatoprost ophthalmic solution) 0.01% as a... http://pharmalicensing.com/redirs/news_rss//public/news/view/530849/0/1/allergan-inc-receives-fda-approval-for-lumigan-r-0-01-as-first-line-therapy-indicated-for-the-reduction-of-elevated-intraocular-pressure-in-glaucoma-patients http://pharmalicensing.com/redirs/news_rss//public/news/view/530849/0/1/allergan-inc-receives-fda-approval-for-lumigan-r-0-01-as-first-line-therapy-indicated-for-the-reduction-of-elevated-intraocular-pressure-in-glaucoma-patients Bayer Berlin, Germany, August 31, 2010 - The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant rivaroxaban demonstrated non-inferiority compared to the standard of care for the prevention... http://pharmalicensing.com/redirs/news_rss//public/news/view/530731/0/1/bayer http://pharmalicensing.com/redirs/news_rss//public/news/view/530731/0/1/bayer Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study Stockholm, SE (August 31, 2010) -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully... http://pharmalicensing.com/redirs/news_rss//public/news/view/530750/0/1/rivaroxaban-successfully-demonstrated-non-inferiority-compared-to-standard-of-care-for-the-prevention-of-recurrent-venous-thromboembolism-in-pivotal-phase-3-study http://pharmalicensing.com/redirs/news_rss//public/news/view/530750/0/1/rivaroxaban-successfully-demonstrated-non-inferiority-compared-to-standard-of-care-for-the-prevention-of-recurrent-venous-thromboembolism-in-pivotal-phase-3-study Pluristem's Placenta Derived Cells Chosen by European Commission's Seventh Framework Program (FP7) Study for Treatment of Diastolic Heart Failure (DHF) in Type 2 Diabetic Patients HAIFA, ISRAEL --August 30, 2010--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that its PLX cell therapy product, derived from human placenta, a non-controversial, non... http://pharmalicensing.com/redirs/news_rss//public/news/view/530711/0/1/pluristems-placenta-derived-cells-chosen-by-european-commissions-seventh-framework-program-fp7-study-for-treatment-of-diastolic-heart-failure-dhf-in-type-2-diabetic-patients http://pharmalicensing.com/redirs/news_rss//public/news/view/530711/0/1/pluristems-placenta-derived-cells-chosen-by-european-commissions-seventh-framework-program-fp7-study-for-treatment-of-diastolic-heart-failure-dhf-in-type-2-diabetic-patients